Table 2.

Clinical characteristics of SARS survivors in 12 years and 18 years after infection.

Characteristics	SARS survivors at 12 years after discharge (n = 14)	SARS survivors at 18 years after discharge (n = 14)	P value
Harris score	62.14 ± 15.39	70.07 ± 21.57	0.23
SF-36 Quality of Life score	33.98 ± 19.13	101.7 ± 29.37	<0.001
Pulmonary function
TLC (%)	80.01 ± 10.35	94.40 ± 27.86	0.09
FVC of predicted/%	95.74 ± 13.30	91.61 ± 17.37	0.31
FEV1 of predicted/%	94.91 ± 11.24	93.33 ± 15.38	0.52
(FEV1/FVC)/%	83.09 ± 8.09	84.49 ± 8.52	0.48
FEV1/VCMAX/%	104.68 ± 10.62	105.24 ± 12.99	0.84
FEF50 (%)	93.12 ± 24.86	94.98 ± 32.84	0.80
FEF75 (%)	75.79 ± 33.00	103.75 ± 26.40	0.01
MMEF (%)	87.25 ± 23.06	81.73 ± 36.02	0.59
VC (%)	95.81 ± 14.51	85.16 ± 29.37	0.16
Chest CT
Affected lung lobes	2.71 ± 1.44	2.29 ± 1.38	0.11
The right upper lobe	10 (71.4%)	9 (64.3%)	1.00
The right middle lobe	4 (28.6%)	3 (21.4%)	1.00
The right lower lobe	9 (64.3%)	8 (57.1%)	1.00
The left upper lobe	5 (35.7%)	3 (21.4%)	0.68
The left lower lobe	10 (71.4%)	9 (64.3%)	1.00
Consolidation opacities	2 (14.3%)	3 (21.4%)	1.00
Ground-glass opacities	7 (50%)	7 (50%)	1.00
Ground-glass opacities as the main performance	7 (50%)	7 (50%)	1.00
Consolidation opacities as the main performance	1 (7.1%)	1 (7.1%)	1.00
Subpleural relatively unaffected	10 (71.4%)	12 (85.7%)	0.65
Lobular core nodules	8 (57.1%)	6 (42.9%)	0.71
Semi-quantitative visual score of lung lesions
The right upper lobe lesions	1 (0.25,1)	1 (0,1)	0.77
The right middle lobe lesions	0 (0,0.75)	0 (0,0)	0.77
The right lower lobe lesions	1 (0,1)	1 (0,1)	0.64
The left upper lobe lesions	0 (0,1)	0 (0,0)	0.54
The left lower lobe lesions	1 (0.25,1)	1 (0,1)	0.60
Total score	2.93 ± 1.94	2.29 ± 1.38	0.06